Snell & Wilmer Advises Drug Development Company Brenig Therapeutics, Inc. as it Secures $65 Million in Series A Financing

SAN DIEGO – Snell & Wilmer advised Brenig Therapeutics, Inc. (“Brenig”), a pioneering neurology-focused drug development company utilizing an AI/ML-based discovery platform, as it secured $65 million in Series A financing led by New Enterprise Associates (NEA) with support from an additional US-based healthcare investor as well as existing investors: OrbiMed, Torrey Pines Investments and BioGeneration Ventures. In connection with the financing, Ed Mathers, Partner at NEA, will join the Board of Directors.

“The Brenig team has made remarkable progress since inception,” said Mathers in a recent press release. “We believe their approach could lead to best-in-class therapeutics for the treatment of Parkinson’s disease. NEA is thrilled to partner with Brenig through its next phase of growth”. 

Brenig plans to use the proceeds from this financing to advance BT-267 through healthy volunteer studies and into proof-of-concept studies in idiopathic Parkinson’s disease patients. In addition, the company will explore advancing additional best-in-class approaches for Parkinson’s disease. “With the financing, we advance our goal of addressing the needs of Parkinson’s disease patients with our differentiated drugs,” said Iain Dukes MA DPhil, Chairman of Brenig.  

Partner Bardia Moayedi led the Snell & Wilmer team advising Brenig in the deal. The diverse team included Sarah Hibbard, Eli Mansour, Christopher Franich, Bahar Schippel, and Paralegal Scott Drake.

Snell & Wilmer’s corporate and securities attorneys have served as counsel to a substantial number of clients ranging from Fortune 100 companies to smaller emerging businesses. Our attorneys have provided sophisticated legal representation to biotech companies, health care and financial institutions, public utilities, homebuilders, transportation companies, restaurant and hospitality providers, athletic complexes, fitness facilities and many other types of businesses. Snell & Wilmer’s venture capital and private equity practice covers multiple aspects of the transactional arena involving public and private companies, including the structuring and execution of majority buyouts and minority investments, acquisitions (including buy- and sell-side deals, as well as negotiated and auction deals), financings (including 144A transactions and PIPEs), going-private transactions, and spin-off transactions. Our venture capital and private equity attorneys advise both domestic and international funds, including venture capital, private equity, hedge, mezzanine, real estate opportunity, fund-of-funds, exchange, and other private investment funds.